Sabine Hofmann-Thiel
Research Subjects
Sabine Hofmann-Thiel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Harald Hoffmann
World Hlth Org WHO Supranatl Reference Lab TB, Inst Microbiol & Lab Med IML Red GmbH, Dept Res Educ & Dev, Munich, Germany
2 shared publications- Harald Hoffmann
Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine
2 shared publications Marina Mihalic
World Hlth Org WHO Supranatl Reference Lab TB, Inst Microbiol & Lab Med IML Red GmbH, Dept Res Educ & Dev, Munich, Germany
2 shared publicationsSara Plesnik
World Hlth Org WHO Supranatl Reference Lab TB, Inst Microbiol & Lab Med IML Red GmbH, Dept Res Educ & Dev, Munich, Germany
2 shared publicationsAna R. Homann
Hahn Schickard Gesell Angew Forsch eV, Dept Microfluid Platforms, Freiburg, Germany
1 shared publicationBhabana Shrestha
German Nepal TB Project, Dept TB Diagnost, Kathmandu, Nepal
1 shared publication
Latest Publications
- 1 May 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (5) , 643-650
Rapid Tuberculosis Diagnostics Including Molecular First- and Second-Line Resistance Testing Based on a Novel Microfluidic DNA Extraction Cartridge
- 1 May 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (5) , 643-650
Rapid Tuberculosis Diagnostics Including Molecular First- and Second-Line Resistance Testing Based on a Novel Microfluidic DNA Extraction Cartridge
- 1 October 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (10) , 1280-1286
Clinical Evaluation of BD MAX MDR-TB Assay for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers
- 1 October 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (10) , 1280-1286
Clinical Evaluation of BD MAX MDR-TB Assay for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers
- 1 December 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (12) , 3022-3027
Evaluation of the Abbott RealTi m e MTB and RealTi m e MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens
The Abbott RealTi m e MTB (RT MTB) assay is a new automated nucleic acid amplification test for the detection of Mycobacterium tuberculosis complex (MTBC) in clinical specimens. In combination with the RealTi m e MTB INH/RIF (RT MTB INH/RIF) resistance assay, which can be applied to RT MTB-positive specimens as an add-on assay, the tests also indicate the genetic markers of resistance to isoniazid (INH) and rifampin (RIF). We aimed to evaluate the diagnostic sensitivity and specificity of RT MTB using different types of respiratory and extrapulmonary specimens and to compare performance characteristics directly with those of the FluoroType MTB assay. The resistance results obtained by RT MTB INH/RIF were compared to those from the GenoType MTBDR plus and from phenotypic drug susceptibility testing. A total of 715 clinical specimens were analyzed. Compared to culture, the overall sensitivity of RT MTB was 92.1%; the sensitivity rates for smear-positive and smear-negative samples were 100% and 76.2%, respectively. The sensitivities of smear-negative specimens were almost identical for respiratory (76.3%) and extrapulmonary (76%) specimens. Specificity rates were 100% and 95.8% for culture-negative specimens and those that grew nontuberculous mycobacteria, respectively. RT MTB INH/RIF was applied to 233 RT MTB-positive samples and identified resistance markers in 7.7% of samples. Agreement with phenotypic and genotypic drug susceptibility testing was 99.5%. In conclusion, RT MTB and RT MTB INH/RIF allow for the rapid and accurate diagnosis of tuberculosis (TB) in different types of specimens and reliably indicate resistance markers. The strengths of this system are the comparably high sensitivity with paucibacillary specimens, its ability to detect INH and RIF resistance, and its high-throughput capacities.
- 1 December 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (12) , 3022-3027
Evaluation of the Abbott RealTi m e MTB and RealTi m e MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens
The Abbott RealTi m e MTB (RT MTB) assay is a new automated nucleic acid amplification test for the detection of Mycobacterium tuberculosis complex (MTBC) in clinical specimens. In combination with the RealTi m e MTB INH/RIF (RT MTB INH/RIF) resistance assay, which can be applied to RT MTB-positive specimens as an add-on assay, the tests also indicate the genetic markers of resistance to isoniazid (INH) and rifampin (RIF). We aimed to evaluate the diagnostic sensitivity and specificity of RT MTB using different types of respiratory and extrapulmonary specimens and to compare performance characteristics directly with those of the FluoroType MTB assay. The resistance results obtained by RT MTB INH/RIF were compared to those from the GenoType MTBDR plus and from phenotypic drug susceptibility testing. A total of 715 clinical specimens were analyzed. Compared to culture, the overall sensitivity of RT MTB was 92.1%; the sensitivity rates for smear-positive and smear-negative samples were 100% and 76.2%, respectively. The sensitivities of smear-negative specimens were almost identical for respiratory (76.3%) and extrapulmonary (76%) specimens. Specificity rates were 100% and 95.8% for culture-negative specimens and those that grew nontuberculous mycobacteria, respectively. RT MTB INH/RIF was applied to 233 RT MTB-positive samples and identified resistance markers in 7.7% of samples. Agreement with phenotypic and genotypic drug susceptibility testing was 99.5%. In conclusion, RT MTB and RT MTB INH/RIF allow for the rapid and accurate diagnosis of tuberculosis (TB) in different types of specimens and reliably indicate resistance markers. The strengths of this system are the comparably high sensitivity with paucibacillary specimens, its ability to detect INH and RIF resistance, and its high-throughput capacities.
- Open Access
- 5 February 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 59
Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country
With Fluorotype MTB (FT MTB, HAIN Lifesciences, Germany) a new semi-automated assay for detection of M. tuberculosis complex (MTBC) in clinical specimens has been introduced. In a prospective study, we evaluated the diagnostic performance of FT MTB in a routine diagnostic setting in a low-incidence country.
- 5 February 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 59
Open AccessEvaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country
With Fluorotype MTB (FT MTB, HAIN Lifesciences, Germany) a new semi-automated assay for detection of M. tuberculosis complex (MTBC) in clinical specimens has been introduced. In a prospective study, we evaluated the diagnostic performance of FT MTB in a routine diagnostic setting in a low-incidence country.